Evidence map›Paper›PMID 40525786›Full record

ArticleBlood cancer discovery2025

Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases.

Yoshiaki Usui, Mikiko Endo, Yusuke Iwasaki, Hanae Iijima, Hidewaki Nakagawa, Koichi Matsuda, Yukihide Momozawa

Abstract read
In one paragraph

Article in Blood cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Clinical relevance of mosaic variants detected by exome sequencing.The Journal of allergy and clinical immunology · 2026
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoshiaki Usui *Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0001-6180-0704
Mikiko EndoLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0009-0008-4246-6497
Yusuke IwasakiLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0009-0002-8576-1775
Hanae IijimaLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0002-7640-0882
Hidewaki NakagawaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0003-1807-772X
Koichi MatsudaLaboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-7292-2686
Yukihide Momozawa *Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0001-5638-3504

Funding

Japan Agency for Medical Research and Development (AMED) JP18km0605001Japan Agency for Medical Research and Development (AMED) JP19kk0305010Japan Agency for Medical Research and Development (AMED) JP22ama121015Japan Agency for Medical Research and Development (AMED) JP23ck0106805Japan Agency for Medical Research and Development (AMED) JP23tm0624002Special Postdoctoral Researcher Program at RIKENThe Ministry of Education, Science, Sports, Culture, and Technology of Japan 23K19459The Ministry of Education, Science, Sports, Culture, and Technology of Japan 24K20206The MSD Life Science FoundationThe Takeda Science FoundationThe Yasuda Medical Foundation
6 · The paper itself

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) has broad clinical relevance, and TP53 plays various roles within cells. However, the gene-specific and cross-disease significance of CHIP with TP53 mutations (TP53-CHIP) remains unclear. In this study, we evaluated TP53-CHIP using targeted sequencing data of 140,597 individuals without hematologic neoplasms in BioBank Japan. We identified 1,157 individuals with TP53-CHIP and clarified the characteristics of mutations and carriers. TP53-CHIP was associated with poor overall survival, especially because of lymphoid neoplasms and respiratory disease, in addition to myeloid neoplasms. Significant interactions accompanied by excess risks were observed between TP53-CHIP and lifestyle factors for disease-specific mortality: acetaldehyde exposure (resulting from the interaction between drinking and the germline variant of ALDH2) for myeloid neoplasms and smoking for respiratory disease. The clinical significance of TP53-CHIP was sometimes largely independent of variant allele fractions. These findings elucidate aspects of disease pathogenesis and inform personalized risk management. SIGNIFICANCE: TP53-CHIP contributed to a wide range of outcomes besides myeloid neoplasm mortality. TP53-CHIP, when combined with environmental factors, showed a remarkably higher risk for disease-specific mortality, accompanied by excess risks.

Indexed as

Clonal HematopoiesisMutationTumor Suppressor Protein p53AdultAgedClinical RelevanceFemaleHematologic NeoplasmsHumansMaleMiddle AgedTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID40525786
PMCPMC12209765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.